Revenues are derived from the patent licensing of the syringe to date imo. Going public opens a lot of doors to potential marketing and selling the product themselves. Possible production too imo.
Revenues are undisclosed so anyone saying $2B probably smokes too much weed.
I’m sure licensing the patent has done well enough for them to seek distribution of the technology themselves though. I’d be doing the same thing. imo.
After the merger I see $10-$20 a share here based on what I read about this stick-proof syringe.
News 
Market Data 
Discover 
AI
